Evidence map›Paper›PMID 34584454›Full record

ArticleCancer management and research2021

lncRNA AC007207.2 Promotes Malignant Properties of Osteosarcoma via the miR-1306-5p/SIRT7 Axis.

Youting Dang, Yunping Zhou, Xuehai Ou, Qiang Wang, Dengke Wei, Fei Xie

Abstract read
In one paragraph

Article in Cancer management and research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. The dark side of SIRT7.Molecular and cellular biochemistry · 2024
    Review
  4. Osteosarcoma in a ceRNET perspective.Journal of biomedical science · 2024
    Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Youting DangDepartment of Pediatric Orthopedics, Honghui Hospital, Xi'an Jiao Tong University, Xi'an, Shaanxi, 710054, People's Republic of China.
Yunping ZhouDepartment of Hand Surgery, Honghui Hospital, Xi'an Jiao Tong University, Xi'an, Shaanxi, 710054, People's Republic of China.
Xuehai OuDepartment of Hand Surgery, Honghui Hospital, Xi'an Jiao Tong University, Xi'an, Shaanxi, 710054, People's Republic of China.
Qiang WangDepartment of Hand Surgery, Honghui Hospital, Xi'an Jiao Tong University, Xi'an, Shaanxi, 710054, People's Republic of China.
Dengke WeiDepartment of Hand Surgery, Honghui Hospital, Xi'an Jiao Tong University, Xi'an, Shaanxi, 710054, People's Republic of China.
Fei XieDepartment of Hand Surgery, Honghui Hospital, Xi'an Jiao Tong University, Xi'an, Shaanxi, 710054, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLong non-coding RNAs (lncRNAs) have been implicated in initiation and development of numerous cancers. In the present study, we explored the role of lncRNAs AC007207.2 in osteosarcoma (OS).

methodsGene expression data of OS tissues was downloaded from the TARGET database. All the experiments were repeated at least three times. Data were analyzed using Perl, R, SPSS v12.0 and GraphPad Prism 8 software.

resultsWe found lncRNA AC007207.2 was over-expressed in OS tissues and cell lines, and this phenomenon was associated with the worse prognosis of OS. Moreover, we found that AC007207.2 promotes proliferation and metastasis of OS cells via the miR-1306-5p/SIRT7 axis. Meanwhile, we found miR-1306-5p remarkably inhibits the malignant behavior of OS cells.

conclusionlncRNA AC007207.2 promotes progression of OS by upregulating SIRT7 expression through miR-1306-5p sponging. Thus, lncRNA AC007207.2/miR-1306-5p/SIRT7 axis is a promising therapeutic target for OS treatment.

Indexed as

LncRNA AC007207.2miRNAosteosarcoma

Identifiers

PMID34584454
PMCPMC8464591

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.